<DOC>
	<DOCNO>NCT01033747</DOCNO>
	<brief_summary>The purpose study assess safety effect liver iron Deferasirox give long treatment period patient transfusion dependent iron overload .</brief_summary>
	<brief_title>Safety Efficacy Deferasirox Patients With Transfusion Dependent Iron Overload - Non-comparative Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Patients Currently participate 9month comparative prolongation extension phase original study . Patients currently participate foodeffect substudy , accord amendment 3 . Ability provide write informed consent prior participation noncomparative extension study . Female patient sexually active must use doublebarrier contraception , oral contraceptive plus barrier contraceptive , must undergo clinically document total hysterectomy and/or ovariectomy , tubal ligation . Body weight least 35 kg . Pregnant breastfeeding patient . History noncompliance medical regimen patient consider potentially unreliable . Proteinuria &gt; 300 mg/L second void morning urine . Patients serum creatinine upper limit normal . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>iron overload</keyword>
	<keyword>iron chelation therapy</keyword>
	<keyword>B-thalassemia</keyword>
</DOC>